Federal Register Notice: FDA’s Anesthetic and Analgesic Drug Products Advisory Committee will meet 7/18, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committee will discuss an Organon USA NDA for sugammadex sodium injection for the proposed indications of routine reversal of moderate and deep neuromuscular blockade (NMB) induced by rocuronium or vecuronium and immediate reversal of NMB at three minutes after administration of rocuronium. Contact Yvette Waples, (301) 796-9001. To view this notice, click here.